Janiczek Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Janiczek Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-150	Closed	-$13.1K	–	1093
2024 Q1	$13.1K	Hold	150	–	–	﹤0.01%	635
2023 Q4	$14.5K	Sell	150 -13	-8%	-$1.15K	﹤0.01%	601
2023 Q3	$14.4K	Hold	163	–	–	﹤0.01%	566
2023 Q2	$14.1K	Sell	163 -249	-60%	-$23.4K	﹤0.01%	505
2023 Q1	$40.8K	Sell	412 -176	-30%	-$18.2K	0.01%	341
2022 Q4	$66.8K	Sell	588 -26	-4%	-$2.44K	0.02%	276
2022 Q3	$54K	Buy	614 +464	+309%	+$41.3K	0.02%	291
2022 Q2	$13K	Buy	+150	New	+$11.9K	﹤0.01%	531
2020 Q3	–	Sell	-26	Closed	-$3K	–	647
2020 Q2	$3K	Buy	+26	New	+$2.58K	﹤0.01%	231

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Janiczek Wealth Management's BMRN Position: Q2 2024 in Review

Janiczek Wealth Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 150 shares — an estimated $13.1K sold.

Janiczek Wealth Management first reported a position in BMRN in Q2 2020 and held it in 9 quarters. The position peaked at $66.8K in Q4 2022. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

Janiczek Wealth Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Janiczek Wealth Management sold 150 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $13.1K.
Janiczek Wealth Management first reported a position in BioMarin Pharmaceuticals in Q2 2020 and held it in 9 quarters.
Janiczek Wealth Management's BioMarin Pharmaceuticals position peaked at $66.8K in Q4 2022.
558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on Janiczek Wealth Management's 13F filing for Q2 2024, filed 25 Jul 2024.